Federal cannabis reform appears to be retreating, with House Republicans pushing Section 607 to block rescheduling efforts and Trump signaling only lip service at high-dollar fundraisers. Meanwhile, veterans and patients are left waiting as U.S. growers watch Canadian imports take the stage.

Last week, Donald Trump signaled he is considering rescheduling cannabis from Schedule 1 - a classification shared with heroin and deemed more dangerous than cocaine - to Schedule 3, where prescription drugs like Tylenol with codeine reside. This move could open the door to normalized banking, credit card payments at dispensaries, greater patient access, and potentially unlock sidelined investment capital. U.S. cannabis stocks reacted immediately, with some rising nearly 100%